New incident report
Incident Report Number: 2019-3617
Registrant Reference Number: USA-BAYERBAH-2019-US0034881 (Report 576412)
Registrant Name (Full Legal Name no abbreviations): Bayer inc
Address: 2920 Matheson BLVD
City: Mississaugua
Prov / State: ON
Country: Canada
Postal Code: L5W5R6
Human
Country: UNITED STATES
Prov / State: TENNESSEE
PMRA Registration No. PMRA Submission No. EPA Registration No. 11556155
Product Name: Seresto Collar unknown
Other (specify)
COLLARNo
Unknown
Data Subject
Sex: Male
Age: >6 <=12 yrs / > 6 < = 12 ans
System
>8 hrs <=24 hrs / > 8 h < = 24 h
Unknown
Yes
4
Day(s) / Jour(s)
Non-occupational
Unknown
Unknown
Unknown / Inconnu
Unknown / Inconnu
On approximately, 15-Feb-2019, the boy experienced intermittent grand mal seizures, 1 episode of emesis that resolved approximately 5 minutes post onset and mental impairment. A toxicology blood screening panel and other unspecified blood panel were performed and were both within normal limits. The boy continued to have intermittent seizures and was examined by a pediatrician on emergency. Magnetic Resonance Imaging testing was performed of the brain with the results within normal limits. Approximately 12 hours post onset, the boy recovered. It was unknown if treatments were performed. The boy remained hospitalized for observation.On 19-Feb-2019, the boy was released from the hospital.On 26-Jun-2019, the boy had a follow up exam performed with a pediatric neurologist, anThis morning her son had an appointment with a pediatric neurologist. An electroencephalogram was performed and showed normal brain activity.
Major
N - Unlikely An individual was secondarily exposed to collar, when dog slept in the bed with the boy. Affected site is not in line with exposed site. Reported serious neurological signs are not expected with appropriate product use as not consistent with product's pharmacological profile. The collar is odorless and its active ingredients not volatile at room temperature. Other causes are more likely in individual with concomitant history of digestive tract disorders and elevated blood pressure. Further, emesis is not expected after product exposure, however in this case it may be a consequence of reported seizures. Though, time to onset is short. Considering, no oral exposure and known safety profile of the product and available information, an overall product involvement is unlikely.Preliminary assessment. Pending the final assessment after evaluation by medical doctor. If assessment is changed, the final statement will be submitted.